Biogen | BIIB - Assets



Biogen reported $28.33B in Assets for its fiscal quarter ending in June of 2025.


Assets Change Date
AbbVie USD 136.17B 1B Mar/2025
Acadia Pharmaceuticals USD 1.23B 93.19M Jun/2025
ALKERMES USD 2.25B 170.83M Jun/2025
Amgen USD 87.9B 1.47B Jun/2025
Bayer EUR 105.24B 3.95B Jun/2025
Biogen USD 28.33B 297.1M Jun/2025
BioMarin Pharmaceutical USD 7.46B 309.33M Jun/2025
Bristol-Myers Squibb USD 94.68B 2.25B Jun/2025
Eli Lilly USD 100.92B 11.53B Jun/2025
Gilead Sciences USD 55.72B 713M Jun/2025
Incyte USD 5.82B 71.99M Jun/2025
Merck USD 117.52B 2.4B Jun/2025
Moderna USD 12.01B 694M Jun/2025
Neurocrine Biosciences USD 3.89B 202.1M Jun/2025
Novartis USD 104.4B 4.45B Jun/2025
Pfizer USD 206.1B 1.93B Jun/2025
PTC Therapeutics USD 2.63B 21.23M Jun/2025
Regeneron Pharmaceuticals USD 38.22B 674M Jun/2025
Sanofi 124.96B 6.93B Jun/2025
Sanofi 124.96B 7.84B Jun/2025
Sarepta Therapeutics USD 3.68B 214.43M Jun/2025
Teva Pharmaceutical Industries USD 40.13B 1.72B Jun/2025
Ultragenyx Pharmaceutical USD 1.31B 5.66M Jun/2025
United Therapeutics USD 7.91B 164.1M Jun/2025
Vertex Pharmaceuticals USD 24.04B 1.16B Jun/2025